** Hims & Hers Health (HIMS) shares declining 1.2% on Mon ahead of qtrly results after the bell, as investors watch for signs of subscriber recovery and weight-loss drug sales momentum
** Analysts expect qtrly rev up 44% to $580.2 mln, adj EPS seen at $0.10 vs $0.32 yr-ago, per LSEG; report key after last qtr missed rev ests and saw subscriber losses
** Prev qtrly report on August 4 showed a decline in subscribers in sexual health business, while a move from branded to lower-cost weight loss treatments led to lower revenue per subscriber
** HIMS is shifting to creating copies of Novo Nordisk’s NOVO_B Wegovy weight-loss drug in smaller ‘personalized’ doses after the U.S. Food and Drug Administration sunset the mass compounding it had allowed. NOVO has characterized mass personalization as illegal
** HIMS stock has rallied about 86% YTD, far outpacing S&P 500 SPX up 16%
** Stock recently at 60x expected earnings, below 5-yr avg forward PE of 74
